Keywords: acadia, announces, advances, key, programs, usa-based, pharmaceuticals
Acadia announces advances in two key R&D programs
Article | 27 February 2006
USA-based Acadia Pharmaceuticals says it has selected the novel androgen receptor agonist, ACP-105, as its lead developmental candidate. The drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
